Subscribe To
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027- […] The post Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023 appeared first on ForexTV...
Read More
Posted: Nov 3 2023, 11:00
Author Name: forextv
Views: 112131